Loading…
Telix Pharmaceuticals Ltd
Telix Pharmaceuticals Ltd (TLX) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in North Melbourne, Australia and has 1,120 employees. The company is worth $3.63B and trades at 106.9x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $803.79M in fiscal 2025, up 55.6% from the year before. It reported a net loss of $7.13M. The share price is 18.5% below its 52-week high of $13.11. One of the 38 superinvestors we track held it at the end of Q2 2026: Two Sigma (Two Sigma Investments), at $117.99K. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -35.2% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 2 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $7.49 | $15.40 | |
| P/E | — | — | 157.8x |
| P/S | — | 3.2x | 10.0x |
| P/B | — | 6.1x | 14.6x |
| EPS | -$0.02 | $0.10 | |
| Profit margin | — | -0.89% | 6.52% |
| ROE | — | -1.72% | 9.54% |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings growing 25.0% a year plus a 0.0% dividend yield. Growth capped at 25%.
Median P/E of 24.3 among peers in the sector.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OGNOrganon & Co. | $13.75 | 17.6x | 3.6x | 0.58% | 24.04% | $3.61B |
| LEGNLegend Biotech Corp | $18.90 | — | 3.0x | 0.00% | -8.08% | $3.68B |
| AMLXAmylyx Pharmaceuticals, Inc. | $28.57 | — | 13.3x | 0.00% | -74.73% | $3.59B |
| ABCLAbCellera Biologics Inc. | $11.37 |
Median of the years shown; P/E years above 200x are left out.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
3 methods answered, across 1 families.
Room for errors in the reported numbers.
-79.0% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| — |
| 3.9x |
| 0.00% |
| -17.30% |
| $3.68B |
| CDNACareDx, Inc. | $69.16 | 33.3x | 8.4x | 0.00% | 29.49% | $3.58B |
| VCYTVeracyte Inc | $46.04 | 32.9x | 2.7x | 0.00% | 8.77% | $3.7B |